Neurogene INC 8-K filings

Neurogene Inc. successfully held its 2024 Annual Meeting of Stockholders, electing two Class I directors and ratifying the appointment of Deloitte & Touche LLP as its independent auditor.

Neurogene's NGN-401 gene therapy for Rett syndrome has been chosen for the FDA's START Pilot Program, which aims to accelerate the development of rare disease therapies.

Neurogene announced its first quarter 2024 financial results, highlighted positive safety data from its NGN-401 gene therapy trial for Rett syndrome, and provided updates on its clinical programs and financial position.

Neurogene's NGN-401 gene therapy for Rett syndrome shows a favorable safety profile in early trial data, with no signs of overexpression toxicity in the first three patients.

Neurogene Inc. has amended its consulting agreement with Stuart Cobb, Ph.D., its Chief Scientific Officer, outlining new terms for compensation and termination.

Neurogene's NGN-401 gene therapy for Rett syndrome shows promising initial safety and tolerability in a Phase 1/2 clinical trial, with no serious adverse events reported.

Neurogene Inc. has entered into new employment agreements with its CEO, Rachel McMinn, and CFO, Christine Mikail, outlining their compensation and severance terms.

Neurogene announced its full year 2023 financial results, highlighted clinical trial progress, and confirmed a strong cash position following a reverse merger and private financing.

Neurogene has announced an expansion of its Phase 1/2 clinical trial for NGN-401, a gene therapy for Rett syndrome, and plans to accelerate patient enrollment.

Neurogene Inc. has appointed Donna Cochener as Senior Vice President, General Counsel, effective February 15, 2024.